<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Effect of the new competitive <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) <z:chebi fb="68" ids="48706">antagonist</z:chebi> D-(E)-2-amino-4-<z:chebi fb="36" ids="29309">methyl</z:chebi>-5-phosphono-3-<z:chebi fb="0" ids="25897">pentenoic acid</z:chebi> (CAS 137424-81-8, CGP 40116) was examined in a mongolian gerbil model of global <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Effect of CGP 40116 was compared to that of another competitive <z:chebi fb="0" ids="31882">NMDA</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi>, (+/-)-cis-4-phosphonomethyl-piperadine-2-<z:chebi fb="1" ids="33575">carboxylic acid</z:chebi> (CAS 110347-85-8, CGS 19755) under the same conditions </plain></SENT>
<SENT sid="2" pm="."><plain>Drugs were administered intraperitoneally 30 min before bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>At 4 days after the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, locomotor activity was significantly higher in ischemic control mongolian gerbils in comparison with sham-operated mongolian gerbils </plain></SENT>
<SENT sid="4" pm="."><plain>CGP 40116 at the dose of 10 mg/kg and CGS 19755 at the doses of 10 and 30 mg/kg significantly suppressed the increase of the motility </plain></SENT>
<SENT sid="5" pm="."><plain>Seven days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, ischemic control group was still <z:mp ids='MP_0001399'>hyperactive</z:mp> compared to sham-operated group </plain></SENT>
<SENT sid="6" pm="."><plain>CGP 40116 at the dose of 10 mg/kg and CGS 19755 at the dose of 30 mg/kg significantly reversed it </plain></SENT>
<SENT sid="7" pm="."><plain>The number of survived neurons of ischemic control group was significantly less than that of sham-operated group at 7 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CGP 40116 at the dose of 10 mg/kg and CGS 19755 at the dose of 30 mg/kg significantly increased the number of survived neurons </plain></SENT>
<SENT sid="9" pm="."><plain>It is concluded that CGP 40116 is more potent for amelioration of global cerebral ischemic damage than CGS 19755 </plain></SENT>
</text></document>